ClinicalTrials.gg
RecruitingNCT07172646Updated Jan 6, 2026

A Study of SRSD216 in Patients With Elevated Lipoprotein (a)

A Phase 1/2 interventional study of SRSD216 injection and Placebo in Hyperlipoproteinemia (a), sponsored by Sirius Therapeutics Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-06.

Sponsored by Sirius Therapeutics Co., Ltd. · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by May 2026, 6 months ago, but the record still lists the study as recruiting.
  • Registered 4 months after the study started (first participant enrolled Apr 2025, registered Aug 2025).
  • Started Apr 2025; still recruiting 1 year 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
84
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

This is a two-part study, intended to investigate the safety, tolerability, characteristics of PK and PD of single SC dose of SRSD216 and to identify a dose range for further studies in subjects with elevated Lp(a) level with or without ASCVD history.

02

Conditions studied

  • Hyperlipoproteinemia (a)

Browse trials for

03

In context

Hyperlipoproteinemias

35 studies on the registry are indexed under Hyperlipoproteinemias; 6 are open to participants now.

This study's planned enrollment of 84 is close to the median of 84 across 29 interventional studies indexed under Hyperlipoproteinemias.

Browse Hyperlipoproteinemias studies →

Lead sponsor

Sirius Therapeutics Co., Ltd. is the lead sponsor of 6 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Able to comprehend and willing to sign an form (ICF) and to abide by the study restrictions;
  • Males or females, of any race;
  • (BMI) between 18.0 and 40.0 kg/m2, inclusive;
  • Male subjects are not allowed to donate sperm, and female subjects are not allowed to donate eggs from the time the ICF is signed until at least 3 months after the last follow-up.

Exclusion criteria

Exclusion Criteria:

  • Any history or evidence of abnormal bleeding or coagulopathy; or evidence of prolonged or unexplained, bleeding, or frequent unexplained bruising or thrombosis; or history of spontaneous bleeding;
  • Evidence of active or suspected cancer within 3 years prior to screening (non-melanoma skin cancer, localized prostate cancer treated with curative intent, or other in situ carcinoma that does not require systemic therapy and is considered cured for at least 1 years is allowed);
  • Acute febrile illness within 7 days prior to dose administration or evidence of active infection;
  • Any major surgery within 3 months prior to screening or plan to have any major surgery during the study;
  • History of clinically significant , intolerance, or allergy to any oligonucleotide or GalNAc as determined by the investigator;
  • Fasting TG≥ 500 mg/dL (5.6 mmol/L) during screening;
  • Receipt of an drug within 30 days or 5 half-lives of that drug, whichever is longer, prior to dose administration in this study;
  • Have previously completed or withdrawn from this study or any other study investigating SRSD216 and have previously received SRSD216.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Care provider, Investigator, Outcomes assessor)
Enrollment
84 participants (estimated)

Study arms

  • Experimental
    SRSD216 injection (Part 1)

    SRSD216 administered SC. in subjects of Part 1

    Drug: SRSD216 injection

  • Experimental
    SRSD216 injection (Part 2)

    SRSD216 administered SC. in subjects of Part 2

    Drug: SRSD216 injection · Drug: Placebo

  • Experimental
    0.9% Sodium Chloride (Part 1)

    Placbo administered SC. in subjects of Part 1

    Drug: Placebo

  • Placebo comparator
    0.9% Sodium Chloride (Part 2)

    Placbo administered SC. in subjects of Part 2

    Drug: SRSD216 injection · Drug: Placebo

Interventions

  • DrugSRSD216 injection

    Administered SC.

  • DrugPlacebo

    Administered SC.

06

What researchers measure

Primary outcomes

  1. Incidence of treatment-emergent adverse events (TEAEs)

    A summary of TEAE to evaluate the safety and tolerability of SRSD216

    Time frame: 1 year

07

Study locations

1 of 1 sites recruiting
  • Site 01
    Beijing, Beijing Municipality 100000, China
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2025 (actual). Primary completion is estimated for May 2026, 13 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 21, 2025
First posted
Sep 15, 2025
StartActual
Apr 7, 2025
Primary completionEst.
May 2026
CompletionEst.
Apr 2027
Last update
Jan 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07172646
Lead sponsor
Sirius Therapeutics Co., Ltd.
Responsible party
Sponsor
First posted
Sep 15, 2025
Start date
Apr 7, 2025
Primary completion
May 2026 (estimated)
Completion
Apr 2027 (estimated)
Last update
Jan 6, 2026

Study contacts

Medical Director
Contact
medical@siriusrna.com
+86 21 61207756
Medical Director, MD
study director · Sirius Therapeutics

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion